Page 4 - Nonclinical Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 05, 2021 NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.  . (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Dr. Adebayo (Bayo) Laniyonu, as Senior Vice President for Nonclinical Development. Dr. Laniyonu has over 24 years’ experience with the ...

January Therapeutics Announces Appointment of Dr. Daniel C. Maneval, PhD as Chief Scientific Officer Share Article As Chief Scientific Officer Dr. Maneval will lead key aspects of the Scientific Team for January’s oncology programs SAN DIEGO (PRWEB) April 27, 2021 January Therapeutics today announced the appointment of Daniel C. Maneval, PhD, as Chief Scientific Officer. Dr. Maneval will lead key aspects of the Scientific Team for January’s oncology programs including the JNTX-101 program (pro-drug albumin-encapsulated ver...

April 20, 2021) Inhalation Sciences (ISAB) has signed an agreement with prestigious lead generation company Cience and with Coelus Bio, a boutique CRO consulting firm specialized in inhalation drug development, to generate new leads and sales in the US. It is part of the marketing activities aimed at growing ISAB's sales and presence in the US, a strategic goal for 2021, and becoming a clear market leader in its niche. With strengthened sales in 2020 ISAB identified expanding its marketing and sales activities as a vital strategy for 2021, aiming to expand sales in the US . In December 2020...

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical Development News provided by Share this article Share this article Elliot Ehrich MD brings 25+ years R&D and clinical development leadership experience to the company; Graeme Smith PhD DABT brings 15+ years of nonclinical drug development leadership experience to the company. WALTHAM, Mass., April 13, 2021 /PRNewswire/ -- Skyhawk Therapeutics today announced the appointments of Dr. Elliot Ehrich as its President, and Dr. Graeme Smith as its Senior Vice President of N...

Share this article Share this article NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's disease (PD) based on imaging of brain iron. The funding for US$495,000 will be used to evaluate the pharmacologic profile of ATH434 in a primate model to determine the optimal dose of ATH434 in future Parkinson's disease clinical trials.  This is the second grant t...